Led by Industry Experts
Dr. Pankaj Mohan founded Sonnet BioTherapeutics in 2015 and currently serves as Chief Executive Officer and Chairman. Learn more about our team members by visiting the links provided.
As experts in immune-oncology therapies, our first-wave pipeline comprises five cytokine-derived product candidates, with lead our lead proprietary compound, SON-1010, in Phase 1 development, closely followed by SON-080 in Phase 1b/2a development, and three other compounds undergoing preclinical study.
Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune-oncology; however, our technology is suited for drug development across the spectrum of human disease.
Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a 10-fold increase in half-life and a >30-fold increase in efficacy as compared to recombinant interleukins without FHAB.The versatile platform can generate a large immune-oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence, with a human glycosylation profile that can be manufactured using a standard CHO process.